According to the American Thyroid Association guidelines for the management of MTC, yearly screening for PHEO and PHTH should begin by age 11 years for RET PV carriers classified in the ATA high and highest categories and by age 16 years for RET PV carriers in the moderate category [8]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.